Company profile: Inotrem
1.1 - Company Overview
Company description
- Provider of immunotherapies targeting the TREM-1 pathway, including nangibotide, a synthetic peptide and first-in-class TREM-1 inhibitor for acute inflammatory syndromes (septic shock, severe COVID-19); a monoclonal antibody program for chronic inflammatory and fibrotic diseases and immuno-oncology; and a companion diagnostic with Roche Diagnostics measuring soluble TREM-1 in blood to identify septic shock patients.
Products and services
- Nangibotide: Produces a first-in-class synthetic peptide TREM-1 inhibitor that treats septic shock and severe COVID-19 by restoring a balanced inflammatory response in acute inflammatory syndromes
- Companion Diagnostic Tool: Architects a biomarker-assay co-developed with Roche Diagnostics measuring soluble TREM-1 receptor in blood to identify septic shock patients likely to benefit from nangibotide treatment
- Monoclonal Antibody Program: Develops monoclonal-antibody therapeutics inhibiting the TREM-1 pathway to target chronic inflammatory diseases, fibrotic diseases, and immuno-oncology indications within Inotrem's proprietary immunomodulation platform
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Inotrem
Argenx
HQ: United States
Website
- Description: Provider of immunology therapies for severe autoimmune diseases and cancer, including efgartigimod, an investigational antibody fragment targeting FcRn for severe autoimmune diseases with pathogenic IgG autoantibodies; ARGX-117, a humanized sweeping antibody inhibiting C2 and downstream complement in IgM-driven diseases; and empasiprubart, a human IgG1 anti-C2 sweeping antibody with enhanced FcRn binding to improve C2 clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Argenx company profile →
Arsanis
HQ: Austria
Website
- Description: Provider of biopharmaceutical infectious disease treatments based on bacterial protein and carbohydrate antigens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arsanis company profile →
Intrommune Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology, based in New York.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intrommune Therapeutics company profile →
Iconic Therapeutics
HQ: United States
Website
- Description: Provider of TF-targeting immunoconjugate proteins and monoclonal antibodies for diseases with Tissue Factor overexpression. Offers a licensed anti-TF fusion protein (hI-con1) from Yale; ophthalmology program for retinal diseases (AMD, diabetic retinopathy); inflammation program to modulate cytokines/chemokines; and an oncology program with Exelixis developing an ADC for solid tumors, in Phase I.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iconic Therapeutics company profile →
Crescendo Biologics
HQ: United Kingdom
Website
- Description: Provider of Humabody VH-based antibody therapeutics and a discovery platform enabling rapid discovery of fully human VH domains for small, stable multi-specifics. Offerings include CB307 (PSMA x CD137 bispecific in trial for metastatic castration-resistant prostate cancer), CB213 (preclinical PD-1 x LAG-3), and ZL-1102 (topical IL-17A; licensed to Zai Lab). Also engages in partnered and licensed programs with BioNTech, Takeda.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crescendo Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Inotrem
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Inotrem
2.2 - Growth funds investing in similar companies to Inotrem
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Inotrem
4.2 - Public trading comparable groups for Inotrem
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →